LivaNova appeared to be the Corporate Investor, which was created in 1987. The venture was found in Europe in United Kingdom. The main office of represented Corporate Investor is situated in the London.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually.
The standard case for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, UCB Pharma, U.S. Venture Partners (USVP). In the next rounds fund is usually obtained by Venture Partners, Sofinnova Partners, Sectoral Asset Management.
The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight HighLife, MD Start, ShiraTronics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Medical, Manufacturing.
Related Funds
Fund Name | Location |
Caxton Advantage Life Sciences Fund | New York, New York, United States |
Five Arrows Principal Investments | France, Ile-de-France, Paris |
Gofar Holdings | China, Guangdong, Guangzhou |
Hunan Zhongai Social Impact Investment | China, Fujian, Hunan |
Hydrogen Capital Partners | Luxembourg, Luxembourg |
Noventi Ventures | - |
Owl Ventures | California, San Francisco, United States |
RCM Business | Bhilwara, India, Rajasthan |
Singh Capital Partners | Maryland, Potomac, United States |
Steelpoint Capital Partners | California, Solana Beach, United States |
Sud Angels | France, Languedoc-Roussillon, Montpellier |
UnityVC | Beijing, Beijing, China |
West Elk Partners | - |
WRD Capital | - |
Yahui Precision Medicine Fund | China, Yunnan, Zhaotong |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Cadence Neuroscience | $26M | 28 Feb 2023 | Washington, United States | ||
Noctrix Health | $17M | 11 Jan 2021 | San Francisco, California, United States | ||
ShiraTronics | $41M | 24 Oct 2019 | Minneapolis, Minnesota, United States | ||
Ceribell | $35M | 25 Sep 2018 | Mountain View, California, United States | ||
HighLife | $14M | 30 Oct 2017 | Ile-de-France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Cadence Neuroscience | $26M | 28 Feb 2023 | Washington, United States | ||
Noctrix Health | $17M | 11 Jan 2021 | San Francisco, California, United States | ||
ShiraTronics | $41M | 24 Oct 2019 | Minneapolis, Minnesota, United States | ||
Ceribell | $35M | 25 Sep 2018 | Mountain View, California, United States | ||
HighLife | $14M | 30 Oct 2017 | Ile-de-France |